Dr. Porcu's research focuses on T-cell lymphomas, extranodal NK/T-cell lymphoma, and Epstein-Barr virus (EBV)-associated lymphomas. He has been instrumental in developing and leading clinical trials investigating novel therapies targeting these malignancies. Notably, he has contributed to studies on duvelisib, a dual PI3K-d,g inhibitor, and targeted treatments combining nanatinostat and valganciclovir for EBV-positive lymphoid malignancies . Additionally, he has been involved in establishing the Philadelphia T-cell Lymphoma/Leukemia Initiative, aiming to address knowledge gaps and improve patient care in T-cell lymphomas and leukemias woth clinical interest in encompasses a broad spectrum of hematologic malignancies, including acute and chronic leukemia, lymphoma, and multiple myeloma.
Pierluigi Porcu, MD
Director, Division of Hematologic Malignancies
Professor
Contact Information
Honickman Center
1101 Chestnut Street
14th Floor
Philadelphia, PA 19107
215-955-8874
215-955-9641 fax
Director, Division of Hematologic Malignancies
Professor
RESEARCH & CLINICAL INTEREST
Education
Medical School
University of Torino Medical School, Torino, Italy - 1987
Residency
Indiana University
Fellowship
Indiana University
Most Recent Peer-Reviewed Publications
- CD38 in the pathobiology of cutaneous T-cell lymphoma and the potential for combination therapeutic intervention: LYMPHOMA
- Short-course subcutaneous alemtuzumab induces clinical responses in relapsed T-cell large granular leukemia
- Identifying Targetable Vulnerabilities to Circumvent or Overcome Venetoclax Resistance in Diffuse Large B-Cell Lymphoma
- The role of interleukin-15 in the development and treatment of hematological malignancies
- Disease characteristics, prognosis, and response to therapy in patients with large-cell transformed mycosis fungoides: A single-center retrospective study
Board Certifications
Medical Oncology
Internal Medicine
Hematology